Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

87 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Determination of an optimal dosing regimen for fexinidazole, a novel oral drug for the treatment of human African trypanosomiasis: first-in-human studies.
Tarral A, Blesson S, Mordt OV, Torreele E, Sassella D, Bray MA, Hovsepian L, Evène E, Gualano V, Felices M, Strub-Wourgaft N. Tarral A, et al. Among authors: felices m. Clin Pharmacokinet. 2014 Jun;53(6):565-80. doi: 10.1007/s40262-014-0136-3. Clin Pharmacokinet. 2014. PMID: 24535888 Free PMC article. Clinical Trial.
Evaluation of the effects on the QT-interval of 4 artemisinin-based combination therapies with a correction-free and heart rate-free method.
Funck-Brentano C, Ouologuem N, Duparc S, Felices M, Sirima SB, Sagara I, Soulama I, Ouedraogo JB, Beavogui AH, Borghini-Fuhrer I, Khan Y, Djimdé AA, Voiriot P. Funck-Brentano C, et al. Among authors: felices m. Sci Rep. 2019 Jan 29;9(1):883. doi: 10.1038/s41598-018-37113-5. Sci Rep. 2019. PMID: 30696921 Free PMC article.
Determination of the Optimal Single Dose Treatment for Acoziborole, a Novel Drug for the Treatment of Human African Trypanosomiasis: First-in-Human Study.
Tarral A, Hovsepian L, Duvauchelle T, Donazzolo Y, Latreille M, Felices M, Gualano V, Delhomme S, Valverde Mordt O, Blesson S, Voiriot P, Strub-Wourgaft N. Tarral A, et al. Among authors: felices m. Clin Pharmacokinet. 2023 Mar;62(3):481-491. doi: 10.1007/s40262-023-01216-8. Epub 2023 Feb 10. Clin Pharmacokinet. 2023. PMID: 36763327 Free PMC article. Clinical Trial.
A PSMA-targeted Tri-specific Killer Engager enhances NK cell cytotoxicity against prostate cancer.
Phung SK, Zorko NA, Soignier Y, Waller RL, Shackelford M, Walker JT, Nelson TD, Selleck C, Bendzick LE, Kotz LE, Kile QM, Bozicevich AJ, Miller SE, Khaw M, Shetty M, Hinderlie P, Ehrhardt M, Li Y, Luo X, Dehm SM, Antonarakis ES, Kennedy PR, Miller JS, Felices M. Phung SK, et al. Among authors: felices m. Cancer Immunol Res. 2024 Nov 15. doi: 10.1158/2326-6066.CIR-24-0273. Online ahead of print. Cancer Immunol Res. 2024. PMID: 39545924
Metabolic programs drive function of therapeutic NK cells in hypoxic tumor environments.
Kennedy PR, Arvindam US, Phung SK, Ettestad B, Feng X, Li Y, Kile QM, Hinderlie P, Khaw M, Huang RS, Kaufman M, Puchalska P, Russell A, Butler J, Abbott L, McClure P, Luo X, Lu QT, Blazar BR, Crawford PA, Lim J, Miller JS, Felices M. Kennedy PR, et al. Among authors: felices m. Sci Adv. 2024 Nov;10(44):eadn1849. doi: 10.1126/sciadv.adn1849. Epub 2024 Oct 30. Sci Adv. 2024. PMID: 39475618 Free PMC article.
N-803, an IL-15 Superagonist Complex as Maintenance Therapy After Allogeneic Donor Stem Cell Transplant for Acute Myeloid Leukemia or Myelodysplastic Syndrome; A Phase 2 Trial.
Merino A, Brunstein CC, Shanley R, Rashid F, Wangen R, Bachanova V, Juckett M, Maakaron J, Felices M, Weisdorf D, Miller JS. Merino A, et al. Among authors: felices m. Transplant Cell Ther. 2024 Dec;30(12):1206.e1-1206.e12. doi: 10.1016/j.jtct.2024.09.023. Epub 2024 Oct 1. Transplant Cell Ther. 2024. PMID: 39362494 Clinical Trial.
87 results